* Lipoxen shares more than double after vaccine study result
* PuriCore says disinfectant product works on Swine flu
* Puricore shares up 40 percent
(Adds details, PuriCore statement)
LONDON, April 30 (Reuters) - Shares in Lipoxen LIPX.L more than doubled on Thursday after the company released trial data showing that a vaccine could work on swine flu.
The company saw shares rise 110 percent by 0828 GMT after the data, which showed that the vaccine created an enhanced level of immunity in animals against an early strain of H1N1 virus, the same type as human swine flu.
It said it is in talks with major vaccine manufacturers and, while it would normally take several years to get the vaccine approved, this process could be accelerated in the event of a major pandemic.
Lipoxen said that the vaccine was suitable for a pandemic because it could be ten times more effective than previous versions.
“The company is in licensing discussions. It’s possible that in an emergency, development could be accelerated. Although in reality it’s likely to be some time away from the market,” said Shawn Manning, an analyst at Singer Capital Markets.
PuriCore PURI.L shares were up 40 percent by 0828 GMT after it released a statement underlining the fact that its Sterilox sanitation technology works on the swine flu virus. (Reporting by Ben Deighton, editing by Mike Nesbit)